Drug intelligence / Profile preview

N,N-dimethyltryptamine nicotinate

Development stage
Unknown
Lead developer
Algernon NeuroScience
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Intravenous (investigational)
01

Overview

N,N-dimethyltryptamine nicotinate is a novel salt form of the psychedelic compound N,N-dimethyltryptamine (DMT), in which DMT is paired with the counterion nicotinate (derived from niacin/vitamin B3). This salt form was developed to potentially improve physicochemical properties such as stability, efficacy, and safety compared to other DMT salts. DMT itself is a potent serotonergic hallucinogen that acts primarily as an agonist at serotonin 5-HT2A receptors and also interacts with sigma-1 receptors. The addition of the bioactive counterion, nicotinate, may provide additional neuronal activity or neuroprotective effects independent of DMT. This combination is being investigated for its potential use in treating acute ischemic stroke and possibly other neurological conditions[7][9].

Other names
DMT nicotinatedimethyltryptamine nicotinate
02

Targets

HTR2A (Serotonin receptor 5-HT2A)SIGMAR1 (Sigma non-opioid intracellular receptor 1)

Beyond the preview

Go deeper on N,N-dimethyltryptamine nicotinate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on N,N-dimethyltryptamine nicotinate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call